SaleJun 17, 2026, 04:52 PM
Ascendis Pharma Sells Rare Pediatric Disease PRV for $187.5M
AI Summary
Ascendis Pharma A/S announced the completion of the previously disclosed sale of its Rare Pediatric Disease Priority Review Voucher (PRV). The company received $187.5 million in cash from an undisclosed buyer, prior to transaction-related expenses. This PRV was granted by the U.S. Food and Drug Administration in February 2026, following the approval of YUVIWEL (navepegritide).
Key Highlights
- Ascendis Pharma completed the sale of its Rare Pediatric Disease Priority Review Voucher (PRV).
- The PRV was sold for $187.5 million in cash, before transaction-related expenses.
- The buyer of the PRV remains undisclosed.
- The PRV was awarded by the U.S. FDA in February 2026.
- The award followed the approval of YUVIWEL (navepegritide).
Price Impact
More from ASND
Clinical TrialJun 15, 6:12 AM
Ascendis Pharma TransCon PTH Phase 3 shows sustained efficacy at Week 182
Clinical TrialJun 13, 4:01 PM
Ascendis Pharma TransCon PTH Phase 3 data shows 86% response rate
Clinical TrialJun 11, 4:02 PM
Ascendis Pharma TransCon PTH shows sustained 5-year efficacy in Phase 2 trial